Developing a nontypeable Haemophilus influenzae (NTHi) vaccine

Search Swinburne Research Bank

Home

Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.3/227521

Title: Developing a nontypeable Haemophilus influenzae (NTHi) vaccine
Author(s): Poolman, J. T.; Bakaletz, L.; Cripps, A.; Denoel, P. A.; Forsgren, A.; Kyd, J.; Lobet, Y.
Abstract: There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, ...) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.
Publication type: Journal article
Source: Vaccine, Vol. 19, supplement 1 (Dec 2000), pp. S108-S115
Publication year: 2000
FOR Code(s): 06 Biological Sciences; 07 Agricultural and Veterinary Sciences; 11 Medical and Health Sciences
Keyword(s): Animal models; Haemophilus influenzae; LPD; LB1/fimbrin/P5; NTHi; OMP26; Otitis; Vaccine research
Publisher: Elsevier
ISSN: 0264-410X
Publisher URL: http://dx.doi.org/10.1016/s0264-410x(00)00288-7
Peer reviewed